Deals
GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Earlier this month, Pfizer’s chairman and CEO, Ian Read, said he was considering selling the company’s Consumer Healthcare business, or possibly spinning it off.
Stryker picked up controlling interest in Vexim, a French medical device company that specializes in the minimally invasive treatment of vertebral fractures.
Danish company Ambu plopped down $265M to acquire Germany-based Invendo Medical, a privately-held medtech company that develops single-use high definition endoscopy products.
scPharmaceuticals filed recently with the SEC regarding its plans for an IPO.
WuXi AppTec, a China CRO/CMO, will acquire ResearchPoint Global, of Texas, a global clinical-stage contract research company, to extend the reach of its own clinical CRO coverage.
TPG Capital has acquired all the outstanding shares of Exactech common stock for $42 per share.
Two privately-held biotechs have merged to tackle recurrent C. difficile infections.
GIMDx of Carlsbad, California acquired exclusive China OEM and distribution rights to oncology diagnostic products made by IncellDx, a Menlo Park company.
Two factors have increased speculation that Smith & Nephew may be ready for a takeover.